A. Mourad, Y. , T. A. , and S. A. , Acute tumor lysis syndrome in large B-cell

A. Cw, A. De, F. K. , and P. L. , Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab, Cancer Immunol Immunother, vol.55, issue.6, pp.717-744, 2006.

A. A. and H. Rs, To kill a tumor cell: the potential of proapoptotic receptor agonists, J Clin Inv, vol.118, issue.6, pp.1979-90, 2008.

B. Ag, E. Na, and B. Vn, Catalytic heterogeneity of polyclonal DNAhydrolyzing antibodies from the sera of patients with multiple sclerosis, Immunol Lett, vol.76, pp.163-170, 2001.

B. Ci, H. Mc, and W. Ra, The neu oncogene encodes an epidermal growth factor receptor-related protein, Nature, vol.319, pp.226-256, 1986.

B. J. , T. D. , M. J. Baughman-s, and . Benz-cc, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J Clin Oncol, vol.14, pp.37-44, 1996.

B. Jn, S. F. , and G. I. , Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin), Br J Haematol, vol.116, p.924, 2002.

B. D. , D. C. , and B. Jm, Utilisation des anticorps monoclonaux pour le traitement des cancers, Immunologie des cancers, pp.203-216, 2003.

B. D. Cd-rom, Les anticorps monoclonaux : nouvelles approches thérapeutiques, 2002.

B. G. and B. Le, Tumorigenesis and the angiogenic switch, Nat Rev Cancer, vol.3, pp.401-410, 2003.

B. Nl, G. Aj, W. Ca, and B. , Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-hodgkin's lymphoma, Ann Oncol, vol.9, issue.9, pp.995-1001, 1998.

B. C. Bondarenko-i, M. A. , and H. Jt, Fluorpuracil, leucovirin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

B. Ja, H. Pm, and G. J. , Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med. Feb, vol.9, issue.3546, pp.567-78, 2006.

B. Al, Z. A. , E. E. , M. E. , D. Mjs et al., Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia, Br J Haematol, vol.96, pp.617-626, 1997.

B. Mr, K. P. , and D. Hollander-w, Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOV18 IgG and F(ab') 2 fragments in ovarian carcinoma patients, Cancer Res, vol.53, pp.5413-5421, 1993.

B. Jc and J. J. Shinn-ca, Campath-1H induces apoptosis in human chronic lymphocytic leukaemia cells (CLL) in vitro independent of complement mediated lysis or Fc? receptor ligation, Blood, vol.94, issue.1, p.126, 1999.

C. G. Blasco, H. , P. G. , W. H. , and L. , Pharmacokinetics of rituximab and its clinical use thought for the best use?, Crit Rev Oncol Hematol, vol.62, issue.1, pp.43-52, 2007.

C. B. , W. M. Ojeda-m, M. B. , and B. F. , Campath-1H in the treatment of Tprolymphocytic leukemia (T-PLL), Blood, vol.94, issue.1, p.125, 1999.

C. Ap, PEGylated antibodies and antibody fragments for improved therapy: a review

C. Bd, Radioimmunotherapy of non-Hodgkin lymphomas, Blood, vol.101, pp.391-399, 2003.

C. Z. Asco, Herceptin in Gastric Cancer ? Practice Changing Data, Disponilbe sur le site, p.703845, 2009.

C. As, W. K. , S. S. , and D. Pa, Constitutive and inductible Akt activity promoters to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells, Mol Cancer Ther, vol.1, pp.707-724, 2002.

C. Ma, Multinational study of the efficacity and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol, vol.17, pp.2639-2687, 1999.

C. L. , Y. Tl, C. E. Liao-yc, G. A. Mcgrath, and J. , Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science, vol.230, pp.1132-1141, 1985.

D. Jong, J. Van-diest, . Pj, . Van-der, and . Valk-p, Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis, The Journal of Pathology, vol.12, issue.1, pp.53-60, 1998.
DOI : 10.1200/JCO.1994.12.3.454

D. V. , V. Degorges, A. , and B. P. , Trastuzumab (Herceptin®) et cancer du sein: mécanismes de résistance, Bull Cancer, vol.94, issue.3, pp.259-66, 2007.

D. Cr, W. S. , and K. M. , Phase I and imaging trial of indium 111-labelled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma

D. Jy, C. Jf, L. Synthèses, D. Ja, K. et al., utilisation des anticorps ou de leurs fragments pour le traitement des tumeurs Pharmacokinetics of gemtuzumab ozogamicin, an antibody targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse, Bulletin du cancer J Clin Pharmacol, vol.85, issue.4111, pp.951-960, 1998.

D. A. , G. R. , J. Dh, B. A. Schiller-jh, and S. Ab, Prospective correlative assesment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel +/-bevacizumab in advanced non-small cell lung cancer (NSLCC), J Clin Oncol, 2006.

F. F. , C. X. , A. P. , C. B. , and M. Jl, Évaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2, Bulletin du Cancer Juillet-Août, vol.94, issue.7, pp.711-731, 2007.

G. V. and W. Es, Multiple roles for the major histocompatibility complex class I-related receptor FcRn, Annu Rev Immunol, vol.18, pp.739-66, 2000.

G. Bj, C. Pj, and M. Nj, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, vol.25, issue.12, pp.1539-1583, 2007.

G. Rm, S. Ka, C. Mh, and P. R. Keegan-p, FDA drug approval summary: panitumumab (Vectibix), Oncologist, vol.12, issue.5, pp.577-83, 2007.

G. Ms, M. D. , A. C. , and M. Ua, Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status, J Clin Oncol, vol.24, issue.26, pp.4324-4356, 2006.

G. Aj, W. Ca, and . Varns-c, Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma, Semin Oncol, vol.5, issue.14, pp.66-73, 1999.

H. G. , X. Mq, and T. Hp, The Campath antigen (CD52), Tissue Antigens, vol.35, pp.1-10, 1990.

H. G. , D. Mjs, C. M. , and P. Jm, Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H, Lancet, vol.2, pp.1394-1403, 1988.

H. D. and W. Ra, The Hallmarks of Cancer, Cell, vol.100, pp.57-70, 2000.

H. Rs, N. R. Davies-am, D. Tp, and S. Jh, Efficacy and safety of singleagent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res, pp.6175-81, 2007.

H. Rs, Monoclonal antibodies to target epidermal growth factor receptor-positive tumors : a new paradigm for cancer therapy. Cancer, pp.1593-611, 2002.

H. Fr, F. Wa, V. R. , V. , and B. Pa, HER-2/neu expression in lung tumors, Semin Oncol, vol.29, pp.51-59, 2002.

H. Sj and Y. A. Jain-v, Efficacity and Safety of Tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab, J Clin Oncol, vol.23, pp.712-719, 2005.

H. H. and F. L. Novotny-w, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, vol.350, pp.2335-2377, 2004.

I. Ej and T. S. Wu-z, Expression of the neonatal Fc receptor, FcRn, on human intestinal cells, Immunology, vol.92, pp.69-74, 1997.

J. Rk, Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy, Nat Med, vol.7, pp.987-989, 2001.

J. Tah and L. Et, Effects of HER-2/neu on chemosensitivity of tumor cells, Drug Resist Update, vol.3, pp.310-324, 2000.

J. Be, J. P. Jones-pt, D. Ph, and F. J. , Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer Replacing the complementarity determining regions in a human antibody with those from a mouse, Clin Cancer Res Nature, vol.1214, issue.321, pp.4436-4440, 1986.

K. Ms, Z. Ad, P. Ow, S. M. , L. J. et al., Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed lowgrade B-cell non Hodgkin's lympoma, J Clin Oncol, vol.19, pp.3918-3946, 2001.

K. M. , F. I. , J. V. , B. Jl, and B. J. Hillmen, Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

K. K. , H. N. , R. A. Bunn-pa, and N. Mn, A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer, Proc Am Soc Clin Oncol, vol.22, 2003.

K. Js, G. F. , A. Mh, and D. Jf, Production of monoclonal antibodies using a secretion capture report web, Biotechnology (NY), vol.13, issue.8, pp.787-90, 1995.

K. Es, T. Mauer-am, and . Ht, A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer, Proc Am Soc Clin Oncol, p.22, 2003.

. Erbb, HER signaling network of growth factor receptors, Adv Cancer Res, vol.77, pp.25-79, 2000.

K. N. Suzuki-y, T. T. , O. K. , R. C. , and T. Y. , FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells, Am J Physiol Renal Physiol, vol.282, pp.358-65, 2002.

K. and F. Ferrer-l, Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibodymediated pretargetting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial La famille des récepteurs HER-ErbB et ses ligands : mécanisme d'activation, signalisations et dérégulations dans le cancer, Clin Cancer Res Bull Cancer, vol.9, issue.90, pp.3973-81, 2003.

L. J. and D. H. Fernandez-luque-r, Doxorubicin gradients in human breast cancer, Clin Cancer Res, vol.5, pp.1703-1710, 1999.

L. D. , M. Mc, D. J. , B. C. , M. F. et al., La radioimmunothérapie des cancers, J Pharm Clin, vol.24, issue.3, pp.139-183, 2005.

L. Gd, Differential responses of human tumor cells lines to anti-p185HER2 monoclonal antibodies, Cancer Immunother, vol.37, pp.255-63, 1993.

L. Sh, D. G. , and M. R. , Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma, Lancet, vol.341, pp.432-435, 1993.

L. Y. , Z. X. Zhao-y, M. D. , and P. M. , Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin), J Natl Cancer Inst, vol.93, pp.1852-1859, 2001.

L. J. , K. E. , B. M. , and B. Pa, Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia, Blood, vol.100, issue.3, pp.768-73, 2002.

M. M. , J. H. , F. Mh, G. J. , T. N. et al., Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy, Ann Med Interne, vol.154, issue.3, pp.139-186, 2003.

M. En, A. Et-physiologie-humaines, and T. , Blockade of EGF-R signaling with anti-EGF-R monoclonal antibody (MAB) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo, Pro Am Assoc Cancer Res, vol.39, pp.83-565, 1998.

K. Mckeage and P. C. Trastuzumab, Trastuzumab, Drugs, vol.18, issue.20, pp.209-252, 2002.
DOI : 10.2165/00003495-200262010-00008

G. Mclaughlin-p, . Aj, and . Link-bk, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program., Journal of Clinical Oncology, vol.16, issue.8, pp.2825-2858, 1998.
DOI : 10.1200/JCO.1998.16.8.2825

M. Ra, M. Dg, W. R. , and L. R. , Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, N Engl J Med, vol.306, pp.517-522, 1982.

M. Ra and L. R. , Response of cutaneous T cell lymphoma to therapy with hydroma monoclonal antibody, Lancet, vol.2, pp.226-230, 1981.

M. L. , M. G. , P. , and M. Jl, Ciblage des récepteurs tyrosine kinase membranaires : y a-t-il de la résistance dans l'HER2?, Bull Cancer, vol.91, issue.9, pp.685-94, 2004.

M. Sl, J. Mj, H. La, and O. Vt, Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc Natl Ac ad Sci, vol.81, pp.6851-6856, 1984.

M. H. Immunologie-fondamentale, M. Dr, and S. Kr, The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development, Curr Opin Drug Discov Devel

N. Lm and R. J. Hardy-r, A unique cell surface antigen identifying lymphoid malignancies of B cell origin, J Clin Invest, vol.67, pp.134-140, 1981.

N. Lm, S. P. , and H. R. , Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, Cancer Res, vol.40, pp.3147-3154, 1980.

N. Y. , L. Kh, Z. X. , T. M. , E. Fj et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

O. , R. , and C. Wj, Diferential modulation of proliferation, matrix metalloproteinase expression and invasion of human head neck squamous carcinoma cells by c-erbB ligands, Clin Exp Metastasis, vol.17, pp.631-639, 1999.

P. S. , V. Dj, J. Beach-cm, P. Dr, M. Mj et al., Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody, Science, vol.244, p.1158, 1989.

P. R. , D. Mjs, B. R. , T. Pd, E. E. et al., Treatment of T-cell prolymphocytic leukaemia with human CD52 antibody, J. Clin. Oncol, vol.15, pp.2667-72, 1997.

P. Bc and B. S. , Trastuzumab in CSF, J Clin Oncol, vol.18, pp.2350-2351, 2000.

P. Mj, P. M. , and L. , Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer, N Engl J Med, vol.353, pp.1659-72, 2005.

P. Sj, J. Jw, and S. Pg, Selective chemical catalysis by an antibody, Science, vol.234, p.1570, 1986.

P. Jt, Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A 704, Eur J Cancer, 1996.

R. N. and W. D. Brachet-p, Epidermal Growth Factor Modulates the Expression of Vascular Endothelial Growth Factor in the Human Prostate, J Androl, vol.22, pp.432-443, 2001.

R. Cl, Theory and methods for immunization in culture and monoclonal antibody production, J. Immunol. Methods, vol.53, pp.261-291, 1982.

R. L. Thèse-pour-le-diplôme-d-'état-de-docteur-en-pharmacie, U. E. Riechmann-l, C. M. , W. H. , and W. G. , R des Sciences Médicales et Pharmaceutiques d'Angers : anticorps monoclonaux en biologie : actualité et avenir Reshaping human antibodies for therapy, Nature, vol.111, issue.332, pp.323-330, 1988.

R. Cm, R. Soares-hp, and S. R. Le, EGFR targeting of solid tumors, Cancer Control, vol.14, issue.3, pp.295-304, 2007.

S. I. , L. Monoclonaux-de-ratkw=anticorps+monoclonauc+rat, S. , and C. E. Null-d, Disponible sur le site: http://www.gazettelabo.fr/archives/recherche.php? Safety and pharmacokinetics of a intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia, Pediatr Infect Dis J, vol.17, pp.787-91, 1996.

S. Ds and C. F. Brandt-r, Epidermal Growth Factor-related peptides and their receptors in human malignancies, Crit Rev Oncol Hematol, vol.19, pp.183-232, 1995.

S. Ab, G. R. , and B. J. , Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer, NSCLC): An Eastern Cooperative Onclogy Group (ECOG) Trial ? E45999

S. H. , J. Pl, S. Sa, P. D. Vessella-rl, and G. Bm, Correlation of vascular permeability and blood with monoclona antibody uptake by human Clouser and renal cell xenografts, Cancer Res, vol.48, pp.188-93, 1988.

S. D. , L. Hn, P. U. , R. Ra, R. C. Lerner-ra et al., In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy, Proc. Nalt. Acad. Sci. USA, vol.98, p.7528, 2001.

S. Hm, L. Gd, S. Jc, F. Bm, M. D. et al., Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic, Clin Immunol, vol.11, pp.117-144, 1991.

S. Dj, L. , S. S. , F. H. , and P. V. Bajamonde, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, vol.344, pp.783-92, 2001.

S. Dj, Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, pp.707-719, 1989.

S. Dj, Human breast cancer : correlation of relapse and survival with amplification of the HER2/neu oncogene, Science, vol.235, pp.177-82, 1987.

S. Ci, G. Ma, and U. J. , Targeting multiples Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo, Clin Cancer Res, vol.8, pp.1720-1750, 2002.

T. Sc, H. K. , R. Md, and B. Nl, Immunosuppressive toxicity of Campath-1H monoclonal antibody in the treatment of patients with recurrent low-grade lymphoma, Leuk Lymphoma, vol.24, pp.93-101, 1996.

T. If, L. Cm, T. Jk, C. Dsm, and E. Mj, Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy

T. Jl, Anticorps monoclonaux : la nouvelle vague, Biofutur, vol.197, p.10, 2000.

T. Y. Ko-k, K. H. , and H. Dj, Controlled glycosylation of therapeutic antibodies in plants, Arch Biochem Biophys, vol.426, issue.2, pp.266-78, 2004.

T. Gr, L. Lr, C. Bc, and V. Es, Immunotoxins: an update, Ann Rev Immunol, vol.14, pp.49-71, 1996.

T. Jk, C. Dsm, S. H. , and T. If, Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors, Clin Cancer Res, vol.5, pp.1583-1589, 1999.

T. A. , J. Kd, and L. Ra, Catalytic antibodies, Science, vol.234, p.1566, 1986.

T. A. , L. Mr, S. P. , and F. Maj, Primary structure of CD52, J Biol Chem, vol.270, pp.6088-99, 1995.

K. Van-cutsem-e, H. E. Ch, and Z. J. , Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

P. M. Van-cutsem-e, S. S. , H. Y. , and H. A. , Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.13, pp.1658-64, 2007.
DOI : 10.1200/JCO.2006.08.1620

V. Rh, M. Lf, B. Bb, E. Aa, and L. A. , Phase III trial of intraperitoneal therapy with yttrium 90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after surgically defined complete response, J Clin Oncol, vol.24, issue.4, pp.571-579, 2006.

V. Jb, T. J. , and H. R. , Open-label, uncontrolled, multicenter phase III study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy, J Clin Oncol, vol.25, issue.16, pp.2171-2178, 2007.

W. Da, E. Kf, D. Lt, R. Jc, and I. Mird, Radionuclide data and decay schemes, New York Society of nuclear Medecine Inc, p.229, 1989.

W. M. , F. Ghtm, W. U. , J. M. , and M. O. , La transgenèse grâce à Agrobacterium tumefaciens Disponible sur le site : http://www.snv.jussieu.fr/vie Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8), Blood, vol.94, pp.2217-2241, 1999.

W. Te, F. Iw, G. Li, E. C. , and C. Ms, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular

W. Te, G. Li, and C. F. , Randomized controlled trial of Y-90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell-non-Hodgkin's lymphoma, J

W. Ea, C. Schreiber-gj, R. Wl, and . Hv, Monoclonal antibody homodimers: enhanced antitumor activity in nude mice, Cancer Res, vol.53, pp.2560-2565, 1993.

W. Jr, The Epidermal Growth Factor Receptor and its Inhibition in Cancer Therapy

Y. T. , M. De, W. M. , and S. J. , Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Res, vol.52, pp.3402-3410, 1992.

R. Des, C. Du-produit, H. , and L. Roche, Date de première autorisation/ de renouvellement de l'autorisation : 28 août, 2000.

R. Prescribing-information, S. Genentech, L. Isabelle, R. Jean-bernard, S. Vains-responsable-du-collège-d-'enseignement-jean-michel et al., rituxan-prescribing.pdf VECTIBIX® prescribing information, Amgen Disponible sur le site : http://www.vectibix.com/prescribing_information/prescribing_information.html ZEVALIN® prescribing information, Spectrum Pharmaceuticals Disponible sur le site : http://www.zevalin.com/pdf/Zevalin_PI_website.pdf Sites internet : www.geniobio.ac-aix-marseille.fr/immuno/docs/Acmbn.ppt www.ccac.ca, Disponible sur le site, 2007.

L. Pierre, . Physiologie, . Orthopédie, L. Maintien-À-domicile-isabelle, L. Pharmacologie-cardiovasculaire-dominique et al., Chimie physique générale, Chimie thérapeutique Bertrand RIHN ................................................ Biochimie

A. Monique, V. Bactériologie, B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle et al., Chimie thérapeutique, Chimie thérapeutique François BONNEAUX

B. Ariane, B. Cédric, C. Jean-claude, C. Chimie-générale-et-minérale-igor, C. Chimie-analytique-jocelyne et al., Pharmacie clinique

H. Thierry, J. Chimie-organique-frédéric, . Santé, J. Olivier, . Toxicologie et al., Biophysique, Informatique Christine PERDICAKIS ................................... Chimie

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique PROFESSEUR ASSOCIE, Biochimie et Biologie

C. Christophe, Anglais ASSISTANT